{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:01:52Z","timestamp":1777928512657,"version":"3.51.4"},"reference-count":60,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic is a health care emergency across the world. Although mitigation measures, such as social distancing and face masks, have attempted to slow the spread of the infection, cases continue to rise. Children who are otherwise healthy tend to develop a milder acute Coronavirus disease 2019 (COVID-19) infection and have lower mortality rates compared with adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Guidelines and current primary and secondary literature on the treatment of COVID-19 and the multisystem inflammatory syndrome in children were searched and reviewed. There are 6 published pediatric series that included 252 children with acute COVID-19 infection and describe various treatments and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Guidelines recommend treating pediatric patients similarly to adult patients. Currently, no prophylactic drug therapy has been shown to reduce the spread of infection. Treatment options for acute COVID-19 are limited to remdesivir and glucocorticoids for patients who require oxygen and\/or mechanical ventilation. The efficacy of hydroxychloroquine, chloroquine, and azithromycin has not been proven and their safety has been a concern. Other therapies that are being explored include interleukin (IL)-1 and IL-6 inhibitors. In children, an atypical Kawasaki-like disease emerged after recent exposure to SARS-CoV-2 and has been named Multisystem Inflammatory Syndrome in Children (MIS-C). Nine case series, including 418 pediatric patients, described pharmacotherapies used and patient outcomes. These pharmacotherapies included intravenous immune globulin and glucocorticoids and in some patients, IL-1 and IL-6 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Given the paucity of data in children, this article presents currently recommended pharmacotherapies for the treatment of acute COVID-19 infection in adult patients and whenever available, in pediatric patients. Pharmacotherapies used in the treatment of MIS-C in children are also reviewed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/ped.2020.1241","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T09:19:40Z","timestamp":1608283180000},"page":"177-189","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge"],"prefix":"10.1177","volume":"33","author":[{"given":"Gladys","family":"El-Chaar","sequence":"first","affiliation":[{"name":"Department of Clinical Health Professions, St. John's University College of Pharmacy and Health Sciences, Queens, New York, USA."},{"name":"Department of Pharmacy, NYU Langone - Long Island, Mineola, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa045"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"World Health Organization. (2020). Clinical management of COVID-19: interim guidance 27 May 2020. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/332196 (accessed October27 2020).","DOI":"10.15557\/PiMR.2020.0004"},{"key":"e_1_3_3_4_2","unstructured":"Center for Disease Control. Available at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/ (accessed May20 2020)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6914e4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-20"},{"key":"e_1_3_3_7_2","first-page":"1824","article-title":"Pharmacological treatments for coronavirus disease 2019 (COVID-19). A review","volume":"323","author":"Sanders JM","year":"2020","unstructured":"Sanders JM, , Monogue ML, , Jodlowski TZ, et al. Pharmacological treatments for coronavirus disease 2019 (COVID-19). A review. JAMA, 2020; 323:1824\u20131836.","journal-title":"JAMA"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.04.062"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2003717"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1948"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30198-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-020-2172-6"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Chao JY Derespina KR Herold BC et al. Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J Pediatr 2020. https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.039.","DOI":"10.1016\/j.jpeds.2020.05.006"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.07.039"},{"key":"e_1_3_3_15_2","unstructured":"Bhimraj A Morgan RL Shumaker AH et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. idsasociety.org. Available at https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/ (accessed October27 2020)."},{"key":"e_1_3_3_16_2","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/ (accessed August27 2020)."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12815"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.2422"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_3_3_22_2","unstructured":"Remdesivir [EUA Fact sheet]. Foster City CA: Gilead Sciences Inc. 2020."},{"key":"e_1_3_3_23_2","unstructured":"Clinical Resource COVID-19 Pharmacotherapy. TRC Pharmacist's Letter. Resource #360423. 2020."},{"key":"e_1_3_3_24_2","unstructured":"FDA News Release. COVID-19 Update: FDA broadens emergency use authorization for veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. Available at https:\/\/www.fda.gov\/news-events\/press-announcements\/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized (accessed September23 2020)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200645"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"e_1_3_3_28_2","unstructured":"Taketomo CK Hodding JH Kraus DM. Lexicomp Online Pediatric and Neonatal Lexi-Drugs Online. Hudson Ohio: Wolters Kluwer UpToDate Inc. 2020."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1844"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1857"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101663"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101738"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0888-2"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"e_1_3_3_38_2","first-page":"e474","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi G","year":"2020","unstructured":"Guaraldi G, , Meschiari M, , Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet, 2020; 2:e474\u2013e484.","journal-title":"Lancet"},{"key":"e_1_3_3_39_2","first-page":"529","article-title":"Pilot prospective open, single-arm multicenter study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia S","year":"2020","unstructured":"Sciascia S, , Apra F, , Baffa A. Pilot prospective open, single-arm multicenter study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol, 2020; 38:529\u2013532.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_40_2","unstructured":"Roche provides an update on the phase III COVACTA trial of Actemra\/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. Available at https:\/\/www.roche.com\/media\/releases\/med-cor-2020-07-29.htm (accessed September23 2020)."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217706"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-40"},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","unstructured":"Freedberg DE Conigliaro J Sobieszczyk ME et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 2020. https:\/\/doi.org\/10.1101\/2020.05.01.20086694.","DOI":"10.1053\/j.gastro.2020.05.053"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1710"},{"key":"e_1_3_3_48_2","unstructured":"Centers for Disease Control. Multisystem inflammatory syndrome. Available at https:\/\/www.cdc.gov\/mis-c\/hcp\/ (accessed July17 2020)."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021680"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021756"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31094-1"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31103-X"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048360"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa069"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00690-8"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2094"},{"key":"e_1_3_3_57_2","doi-asserted-by":"crossref","unstructured":"Kaushik S Aydin SI Derespina KR et al. Multisystem inflammatory syndrome in children (MIS-C) associated with sars- cov-2 infection: a multi-institutional study from New York City. J Pediatr 2020. https:\/\/doi.org\/10.1016\/j.jpeds.2020.06.045.","DOI":"10.1016\/j.jpeds.2020.06.045"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13220"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000484"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key344"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-0882-1"}],"container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ped.2020.1241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:14:56Z","timestamp":1777677296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ped.2020.1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1089\/ped.2020.1241"],"URL":"https:\/\/doi.org\/10.1089\/ped.2020.1241","relation":{},"ISSN":["2151-321X","2151-3228"],"issn-type":[{"value":"2151-321X","type":"print"},{"value":"2151-3228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}